Transcription Factor Deficit Spurs Tumor Development
By LabMedica International staff writers Posted on 28 Jun 2017 |

Image: A photomicrograph of human breast cancer line MCF-7 cells (Photo courtesy of Wikimedia Commons).
A team of British cancer researchers found that the transcription factor proline-rich homeodomain protein (PRH/HHEX) played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.
Breast tumors progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). In order to study the role of the PRH/HEX transcription factor in this progression, investigators at the University of Birmingham (United Kingdom) adapted a population of human breast cancer MCF-7 cells to under or over produce PRH/HEX.
They reported in the June 12, 2017, online edition of the journal Oncogenesis that transcriptionally inactive phosphorylated PRH was elevated in DCIS and IBC compared with tissues in the normal breast. To determine the consequences of PRH loss of function in breast cancer cells, they induced PRH depletion in their line of MCF-7 cells. They showed that PRH depletion resulted in increased MCF-7 cell proliferation in part at least due to increased vascular endothelial growth factor signaling. Moreover, they demonstrated that PRH depletion increased the formation of breast cancer cells with cancer stem cell-like properties.
In a mouse model, PRH overexpression inhibited the growth of mammary tumors. Taken together, these data indicated that PRH played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.
Senior author Dr. Padma Sheela Jayaraman, senior lecturer in cancer biology at the University of Birmingham, said, "PRH is a protein that controls and regulates when genes are switched on or off. However, prior to our research, the role of this protein in breast cancer has been poorly understood. In the laboratory, we found that when PRH protein levels are reduced in a breast tumor the cells are more able to divide, speeding up the progression of the tumor. Moreover, we identified some of the genes which are regulated by PRH and specifically contribute to the increased cell division."
"We made the significant finding that high levels of PRH actually blocked the formation of the tumors, therefore our data suggests that PRH can block tumor formation in some breast cancers," said Dr. Jayaraman. "We propose that monitoring PRH protein levels or activity in patients with breast cancer could be particularly important for assessing their prognosis. In addition, since PRH is known to be important in multiple cell types, this work has important implications for other types of cancer."
Related Links:
University of Birmingham
Breast tumors progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). In order to study the role of the PRH/HEX transcription factor in this progression, investigators at the University of Birmingham (United Kingdom) adapted a population of human breast cancer MCF-7 cells to under or over produce PRH/HEX.
They reported in the June 12, 2017, online edition of the journal Oncogenesis that transcriptionally inactive phosphorylated PRH was elevated in DCIS and IBC compared with tissues in the normal breast. To determine the consequences of PRH loss of function in breast cancer cells, they induced PRH depletion in their line of MCF-7 cells. They showed that PRH depletion resulted in increased MCF-7 cell proliferation in part at least due to increased vascular endothelial growth factor signaling. Moreover, they demonstrated that PRH depletion increased the formation of breast cancer cells with cancer stem cell-like properties.
In a mouse model, PRH overexpression inhibited the growth of mammary tumors. Taken together, these data indicated that PRH played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.
Senior author Dr. Padma Sheela Jayaraman, senior lecturer in cancer biology at the University of Birmingham, said, "PRH is a protein that controls and regulates when genes are switched on or off. However, prior to our research, the role of this protein in breast cancer has been poorly understood. In the laboratory, we found that when PRH protein levels are reduced in a breast tumor the cells are more able to divide, speeding up the progression of the tumor. Moreover, we identified some of the genes which are regulated by PRH and specifically contribute to the increased cell division."
"We made the significant finding that high levels of PRH actually blocked the formation of the tumors, therefore our data suggests that PRH can block tumor formation in some breast cancers," said Dr. Jayaraman. "We propose that monitoring PRH protein levels or activity in patients with breast cancer could be particularly important for assessing their prognosis. In addition, since PRH is known to be important in multiple cell types, this work has important implications for other types of cancer."
Related Links:
University of Birmingham
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more
Non-Biopsy Approach to Transform Adult Celiac Disease Diagnoses
In the United States, the diagnosis of celiac disease in adults typically relies on a combination of serologic testing and a confirmatory small bowel biopsy during upper endoscopy. In contrast, European... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more